. Author manuscript; available in PMC: 2013 Nov 1.

Published in final edited form as: Ophthalmology. 2012 Sep 19;119(11):2312–2318. doi: 10.1016/j.ophtha.2012.08.022

Table 4.

Longitudinal Analysis on Visual Acuity Change^*

		68 weeks	84 weeks	104 weeks	120 weeks	136 weeks	156 weeks
Ranibizumab + prompt laser treatment	N	157	155	156	143	140	144
Ranibizumab + prompt laser treatment	Estimated mean visual acuity change^**	7.5	7.4	7.2	7.1	7.0	6.8
Ranibizumab + Deferred laser treatment	N	167	160	161	149	143	147
	Estimated mean visual acuity change^**	8.6	8.8	9.0	9.2	9.4	9.7
	Difference (95% CI): Prompt vs. Deferred	−1.0 (−2.6, +0.6)	−1.4 (−3.0, +0.3)	−1.8 (−3.6, +0.1)	−2.1 (−4.1, −0.1)	−2.5 (−4.7, −0.2)	−2.9 (−5.4, −0.4)
	P-value	0.20	0.11	0.06	0.04	0.03	0.02

CI= Confidence interval

Truncated to ±30 letters.

^**

The estimated changes after week 16, which coincide with completion of four mandatory monthly injections in each group; Ranibizumab + prompt laser treatment group: mean visual acuity change is decreasing by 0.4 letters per year; Ranibizumab + deferred laser treatment group: mean visual acuity change is increasing by 0.7 letters per year.